Compared with standard-dose (SD), high-dose radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC), results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) have indicated.
Philadelphia, PA-Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being ...
Compared with standard-dose (SD), high-dose radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC), results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) have indicated.
Philadelphia, PA-Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being ...